Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - cobicistat; emtricitabine; tenofovir alafenamide fumarate; darunavir ethanolate - tablet - 150mg ; 200mg ; 10mg ; 800mg

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

krka, d.d., novo mesto - emtricitabine, tenofovir disoproxil succinate - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - emtricitabine / tenofovir disoproxil krka d. hija indikata fit-terapija ta 'kombinazzjoni antiretrovirali għat-trattament ta' adulti infettati bl-hiv-1. emtricitabine / tenofovir disoproxil krka d. huwa wkoll indikat għall-kura ta ' l-hiv-1 infettati fl-adolexxenti, b'reżistenza għal nrti li dehret jew tossiċitajiet li teskludi l-użu tal-ewwel linja ta'l-aġenti, l-età bejn 12 u < 18-il sena.

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

krka, d.d., novo mesto - emtricitabine, tenofovir disoproxil succinate - hiv infections - antivirals for systemic use - emtricitabine/tenofovir disoproxil krka d.d. is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults.emtricitabine/tenofovir disoproxil krka d.d. is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.

Kanada - Franċiż - Health Canada

janssen inc - darunavir (Éthanolate de darunavir); cobicistat; emtricitabine; ténofovir alafénamide (hémifumarate de ténofovir alafénamide) - comprimé - 800mg; 150mg; 200mg; 10mg - darunavir (Éthanolate de darunavir) 800mg; cobicistat 150mg; emtricitabine 200mg; ténofovir alafénamide (hémifumarate de ténofovir alafénamide) 10mg - antiretrovirals

Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infekcijas - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza indicēts cilvēka imūndeficīta vīrusa 1. tipa (hiv-1) infekcijas ārstēšanai pieaugušajiem un pusaudžiem (no 12 gadu vecuma un vecākiem ar ķermeņa svaru vismaz 40 kg). genotypic testing should guide the use of symtuza.

Unjoni Ewropea - Portugiż - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabina, tenofovir alafenamide - infecções por hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - a symtuza é indicada para o tratamento da infecção pelo vírus do vírus da imunodeficiência humana tipo 1 (hiv-1) em adultos e adolescentes (com idade igual ou superior a 12 kg com peso corporal de pelo menos 40 kg). genotypic testing should guide the use of symtuza.

Unjoni Ewropea - Taljan - EMA (European Medicines Agency)

janssen-cilag international nv - o esposti per lungo tempo, cobicistat, emtricitabina, tenofovir alafenamide - infezioni da hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza è indicato per il trattamento dell'infezione da virus dell'immunodeficienza umana di tipo 1 (hiv-1) negli adulti e negli adolescenti (di età pari o superiore a 12 anni con peso corporeo di almeno 40 kg). genotypic testing should guide the use of symtuza.

Unjoni Ewropea - Spanjol - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabina, tenofovir alafenamide - infecciones por vih - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza está indicado para el tratamiento de la infección por el virus de inmunodeficiencia humana tipo 1 (vih-1) en adultos y adolescentes (a partir de 12 años con un peso corporal de al menos 40 kg). genotypic testing should guide the use of symtuza.

Unjoni Ewropea - Rumen - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabină, tenofovir alafenamide - infecții cu hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza este indicat pentru tratamentul de virusul imunodeficienţei umane de tip 1 de infectare (hiv‑1) la adulţi şi adolescenţi (cu vârsta de 12 ani şi mai în vârstă cu corp greutate cel puţin 40 kg). genotypic testing should guide the use of symtuza.

Unjoni Ewropea - Ġermaniż - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabin, tenofovir alafenamide - hiv-infektionen - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza ist indiziert zur behandlung der infektion mit dem humanen immundefizienzvirus typ 1 (hiv-1) bei erwachsenen und jugendlichen (ab 12 jahren mit einem körpergewicht von mindestens 40 kg).. genotypic testing should guide the use of symtuza.